A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
Sponsor: ENGOT Foundation
This observational or N/A phase trial investigates Ovarian Cancer and is currently actively recruiting participants. ENGOT Foundation leads this study, which shows 9 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Contact Information
- ENGOT Foundation
- GOG Foundation
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Adelaide, Australia , Akashi-shi, Japan , Ann Arbor, United States , Ann Arbor, United States , Austin, United States , Baltimore, United States , Barcelona, Spain , Barcelona, Spain , Barcelona, Spain and 71 more locations